{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "34696528",
  "DateCompleted": {
    "Year": "2021",
    "Month": "11",
    "Day": "04"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "11",
    "Day": "04"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "10",
        "Day": "18"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "2098",
      "10.3390/v13102098"
    ],
    "Journal": {
      "ISSN": "1999-4915",
      "JournalIssue": {
        "Volume": "13",
        "Issue": "10",
        "PubDate": {
          "Year": "2021",
          "Month": "Oct",
          "Day": "18"
        }
      },
      "Title": "Viruses",
      "ISOAbbreviation": "Viruses"
    },
    "ArticleTitle": "COVID-19 in 2021.",
    "Abstract": {
      "AbstractText": [
        "The Special Issue on Vaccines and Therapeutics against Coronaviruses, which was launched in early 2021, has attracted the scientific community at large, and more than 20 manuscripts have been accepted for publication.[...]."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "PanTherapeutics, 1095 Lutry, Switzerland."
          }
        ],
        "LastName": "Lundstrom",
        "ForeName": "Kenneth",
        "Initials": "K"
      },
      {
        "Identifier": [
          "0000-0002-9519-6338"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Yarmouk University, Irbid 21163, Jordan."
          }
        ],
        "LastName": "Aljabali",
        "ForeName": "Alaa A A",
        "Initials": "AAA"
      }
    ],
    "PublicationTypeList": [
      "Editorial"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Switzerland",
    "MedlineTA": "Viruses",
    "NlmUniqueID": "101509722",
    "ISSNLinking": "1999-4915"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "COVID-19 Vaccines"
    },
    {
      "RegistryNumber": "EC 3.4.17.23",
      "NameOfSubstance": "ACE2 protein, human"
    },
    {
      "RegistryNumber": "EC 3.4.17.23",
      "NameOfSubstance": "Angiotensin-Converting Enzyme 2"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Angiotensin-Converting Enzyme 2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "prevention & control",
        "therapy"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Vaccines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Discovery"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Mutation"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Publications"
    },
    {
      "QualifierName": [
        "genetics",
        "metabolism"
      ],
      "DescriptorName": "SARS-CoV-2"
    }
  ],
  "CoiStatement": "The authors declare no conflict of interest."
}